Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Symptoms and General Pathology

Prostatic Neoplasms

Prostatic Hyperplasia

Hyperplasia

Prostatitis

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Prostate health screening

We aim to determine the effectiveness of 2013 "Mag paDRE ka" programme in increasing general public awareness on prostate health and promoting prostate health assessment among Filipino males aged 40 or older.

Convenience sampling method will be applied to collect all completed Philippine Urological Association (PUA) survey forms from the 11 Philippine Board of Urology accredited training institutions. A data collection form for the purpose of this study will be used to extract data from the Philippine Urological Association survey forms. The data collection form for this study will extract data, which include basic demographic characteristics of the patients (such as age and educational attainment), family history of prostate cancer, other medical conditions, history of prior prostate screening/ consultation for Lower urinary tract Symptoms or prostate disease. The International Prostate Symptom scores (IPSS) collected will be stratified according to mild (1-7), moderate (8-19) and severe (20-35) and the Filipino version Quality of Life (QoL) ratings will be stratified according to Grade 1, grade 2 and grade 3. DRE findings including the approximation of prostate size and prostate characteristic findings will be clustered to normal in size (20grams or less) versus enlarged (\>20grams or 2 fingerbreadths in width), nodular vs non-nodular, doughy or hard, and tender versus non-tender.

Participants will be classified according to the following :

1. Target population for screening or not :

   Target population for screening is defined as Filipino males aged 40 years or older, who also had no previous consultation for Lower urinary tract symptoms (LUTS) or prostate cancer screening in the past 12 months
2. Case Finding for significant LUTS or prostate cancer or not :

Case of LUTS or prostate cancer is defined as Filipino males aged 40 years or older with IPSS \> 8, OR, has abnormal Digital rectal exam (DRE) finding, which is defined as nodular OR hard OR tender. However, DRE finding of an enlarged prostate but non-nodular, doughy in character and non-tender will not be considered as a case of LUTS or prostate cancer suspect).

Confidentiality of all data will be assured. The case report forms/ data collection form for this study will not contain any patient identifiers. All patient records will be coded in the electronic database as serial number and PUA-designated Institutional code (i.e. SLMC #0001). Only the investigators of this study and other authorized personnel from PUA will be given access to the study data. The PUA survey forms will be secured, filed and only accessed in PUA secretariat building. The electronic database coded with the data from the data collection from of this study will be set with password, and only the study investigators have access to the password.

2013 Annual National Digital Rectal Exam (DRE) Day Study

2013 Annual National Digital Rectal Exam (DRE) Day: Impact on Prostate Health Awareness and Disease Detection

number of new diagnosed prostate disease (target population) for Pa-DRE ka day screening program.

total number of patient consulted on Pa-DRE ka day with prostate diseases

Total score of international Prostate Symptoms Score of each patients consulted for Prostate screening program (Pa-DRE ka day)

Estimated prostate gland size by digital rectal exam for patients presented to the prostate screening program (Pa-DRE ka day)

Summary of digital rectal exam findings of patients presented to prostate screening program (Pa-DRE ka day)

Philippine Board of Urology

Philippine Urology Residents Association

St. Luke's Medical Center, Philippines

Head, Continuing Medical Education Committee of Philippine Urological Residents' Association

Patients diagnosed with Indolent type will be classified according to Epstein Criteria on histopathology results and National Comprehensive Cancer Network (NCCN) guideline recommended classification

Patients diagnosed with aggressive type will be classified according to Epstein criteria on final histopathology findings and NCCN guideline recommended classification

Patient diagnosed with Acute prostatitis- according to histopathology description of Biopsy result

Patient diagnosed with Chronic prostatitis- according to histopathology description of Biopsy result

Patient diagnosed with Benign Prostatic Nodular Hyperplasia- according to histopathology description of Biopsy result

Michael E. Chua, MD

This study will identify significant clinical parameters and individual risk factors related to certain prostate disease (BPH, prostatitis and prostate cancer). With the identified important correlations, a locally generated bias free nomogram will be constructed for predicting prostate biopsy outcome among Asian men with indications for prostate biopsy. While this study will evaluate the accuracy and predictive value of this novel prostate disease nomogram.

This is a cross-sectional study prospectively collecting data from all patients who had their first Transrectal ultrasound (TRUS) prostate biopsy at the Stone and Prostate Treatment Center of St. Luke's Medical Center-Quezon City . Data will be collected uniformly for the purpose of building a clinical care prostate biopsy database. The indication for prostate biopsy is either a suspicious DRE findings or elevated Prostate specific antigen (PSA) level (\>4.0ng/ml) or both. The clinical information gathered will include the 1. Identified risk factors (age, family history, race, Body Mass Index (BMI) - kg/cm2, prostatitis, and medications) 2. Clinical indicators of prostatic diseases (abnormal digital rectal examination, hypoechoic lesion on transrectal ultrasound), and 3. PSA (ng/ml) and its derivatives (age-specific PSA, PSA density, PSA velocity, Free PSA percentage). (Refer to Data Collection Form). Basic demographic data such as patient's height and weight will be measured using standard weight scale (Detecto 439 Mechanical Scale with Height rod, Webb City MO, USA). A urologist member of the team will perform DIgital Rectal Exam (DRE) on all patients before or after the TRUS. Serum free and total PSA level is measured at the Institute of Pathology using Siemens ADVIA Centaur Free PSA and PSA (Seimens Healthcare Diagnostics, USA) within a month prior to the prostate biopsy. Prior to prostate biopsy, the prostate will be scanned using a biplanar 7.5 Megahertz probe (GE Medical Systems Kretz Ultrasound, Zipf, Austria. Prostate volume is measured by a radiology technician \[member of the staff team\] of the center using the transverse and sagittal planes with the standard equation of measurement for prolate ellipsoid \[width (w) x height (h) x length (l) x 0.523\].

All prostate biopsy will uniformly required 12 cores (extended scheme) or more prostate tissue strips under ultrasound guidance with Fr 18 25cm biopsy device (Bard Urological, US), it is performed systematically to covers lateral and medial aspects of the apex, midgland and base of the right and left prostate lobes. Two additional biopsies are obtained if the ultrasound image or DRE findings indicate suspect areas.

All acquired specimens are placed in a formalin-filled container and sent for histopathologic examination. All specimens are examined by at least 2 board-certified pathologists at the Institute of Pathology to determine the presence of inflammation (acute/chronic prostatitis), other disease entity, or carcinoma (if positive for carcinoma, reading include grade using Gleason score, cancer length in biopsy specimen, percent of cancer involvement. All pathologists are blinded from the clinical indicators of the patients. An intermediate result is further subjected to immunohistostaining for a definitive conclusion. At least two pathologists are required to release the final report.

Data collection and extraction will use the pre-tested and standardized form. All collected forms will be submitted to the Clinical Information Service of St. Luke's Medical Center for encoding and preliminary analysis of incidence and prevalence. Additional analysis will be sent to a third party statistician for validation and reliability check.

Confidentiality of all data acquired will be assured. All patient record will be coded in the database as PIN. Patient name will not be included for encoding into the databank. Only the investigator team and clinical information service section of St. Luke's Medical Center will have access to the data set encoded. Hospital policy on safekeeping of the hospital record will be strictly followed and stored by Medical Record section of the medical center.

Configuration of a New Prostate Disease Nomogram Predicting Prostate Biopsy Outcome

Configuration of a New Prostate Disease Nomogram Predicting Prostate Biopsy Outcome Correlating Clinical Indicators Among Asian Adult Males With Elevated Prostate Specific Antigen (PSA)

Incidence of new diagnosed prostate cancer among patients with indication presented for first TRUS prostate biopsy at stone and prostate treatment center.

Incidence of new diagnosed prostatitis among patients with indication presented for first TRUS prostate biopsy at stone and prostate treatment center.

Incidence of new diagnosed nodular hyperplasia (benign prostatic hyperplasia) among patients with indication presented for first TRUS prostate biopsy at stone and prostate treatment center.

Incidence of new diagnosed synchronous occurrences of prostate diseases (benign prostatic hyperplasia, prostatitis, prostate cancer) among patients with indication presented for first TRUS prostate biopsy at stone and prostate treatment center.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
2013 Annual National Digital Rectal Exam (DRE) Day Study	NCT01886547	Benign Prostati... Prostatitis Prostate Cancer	Prostate health...	40 Years -	St. Luke's Medical Center, Philippines
Configuration of a New Prostate Disease Nomogram Predicting Prostate Biopsy Outcome	NCT01826617	Prostate Cancer Prostatitis Benign Prostati...		18 Years -	St. Luke's Medical Center, Philippines

Spots Global Cancer Trial Database for prostatitis

Every month we try and update this database with for prostatitis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for prostatitis

Every month we try and update this database with for prostatitis cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for prostatitis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.